CagriSema for Weight Loss: What to Know About the Semaglutide Combination Drug

CagriSema is an investigational once-weekly injection that combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analogue. Its phase 3 program has produced large average weight reductions, but the numbers need context: different analyses answer different questions, side effects were common, and the medicine has not yet completed the U.S. approval process. [1] [4] [5]

The short version

The pivotal REDEFINE 1 trial studied adults with overweight or obesity without diabetes. In the analysis that counted outcomes regardless of whether participants stayed on treatment, average weight changed by −20.4% with CagriSema and −3.0% with placebo at 68 weeks. A separate analysis estimating results if everyone adhered produced the often-quoted −22.7% figure. Neither is a promise for an individual. [1] [4]

CagriSema is part of a wider pipeline of combination medicines. Yucca’s comparison of retatrutide and tirzepatide explains why pathway count and cross-trial percentages do not establish that one treatment is better for a particular person. The same rule applies here.

What is CagriSema?

CagriSema is the development name for a fixed-dose combination of two peptide medicines. Semaglutide activates GLP-1 receptors. Cagrilintide is a long-acting amylin analogue. The development rationale is that complementary pathways involved in appetite and fullness may produce more weight loss together than either component alone. That rationale is biologically plausible, but clinical trials—not the mechanism alone—determine benefits and harms. [1] [2] [4]

The pivotal regimen used a once-weekly subcutaneous dose containing 2.4 mg of each component after a 16-week escalation. That is a trial protocol, not a dosing instruction: there is no FDA-approved CagriSema label for routine care. [1] [2] [5]

It is also important not to confuse combination design with convenience. Yucca’s guide to GLP-1 pills versus injections covers practical format questions for approved options; CagriSema remains an investigational injection whose final labeling and use conditions are not yet established.

What REDEFINE 1 found in adults without diabetes

REDEFINE 1 was a 68-week, randomized, double-blind phase 3a trial involving 3,417 adults. Participants had obesity, or overweight plus at least one weight-related complication, and did not have diabetes. They received CagriSema, semaglutide alone, cagrilintide alone, or placebo, alongside lifestyle intervention. [1]

In the treatment-policy analysis—designed to reflect the assigned treatment regardless of discontinuation or other changes—the estimated average body-weight change was −20.4% with CagriSema and −3.0% with placebo. The corresponding estimates were −14.9% with semaglutide and −11.5% with cagrilintide. The trial established superiority to placebo; the active-component figures help describe the data but should not be turned into a personalized ranking. [1]

Novo Nordisk also highlights an “if all adhered” analysis: −22.7% with CagriSema versus −2.3% with placebo, with more than 40% reaching at least 25% weight loss. This is a different estimand, not a correction to the −20.4% result. The two figures answer different questions about treatment use, so a headline should name which analysis it uses. [1] [4]

What REDEFINE 2 found with type 2 diabetes

REDEFINE 2 enrolled 1,206 adults with a BMI of at least 27 and type 2 diabetes. Participants were randomized 3:1 to CagriSema or placebo for 68 weeks, with lifestyle intervention. Unlike REDEFINE 1, it did not include semaglutide-alone or cagrilintide-alone comparison groups. [2]

The treatment-policy analysis estimated average body-weight changes of −13.7% with CagriSema and −3.4% with placebo. The share reaching an HbA1c of 6.5% or lower was 73.5% with CagriSema and 15.9% with placebo. These results belong to a type 2 diabetes population and should not be substituted for the REDEFINE 1 estimates from participants without diabetes. [2]

Side effects and the limits of the trial evidence

Gastrointestinal adverse events were common. In REDEFINE 1, they occurred in 79.6% of the CagriSema group and 39.9% of the placebo group. In REDEFINE 2, the corresponding figures were 72.5% and 34.4%. The reports described most events as transient and mild or moderate, but high frequency still matters when considering tolerability and continuation. [1] [2]

A 68-week trial can identify common events and measure average efficacy, but it cannot fully settle rare harms, long-term maintenance, real-world persistence, access, or what happens after stopping. Both pivotal trials were funded by Novo Nordisk, and sponsor employees participated in their design, analysis, and reporting. Peer review and prespecified methods strengthen the evidence; sponsorship remains relevant context. [1] [2]

What the tirzepatide head-to-head study changed

REDEFINE 4 directly compared CagriSema with tirzepatide in 809 adults with obesity and at least one comorbidity. According to Novo Nordisk’s February 2026 headline release, average weight loss at 84 weeks was 23.0% with CagriSema and 25.5% with tirzepatide. The trial did not meet its primary endpoint of showing that CagriSema was noninferior to tirzepatide. [3]

This is more informative than comparing separate trials, but it still deserves restraint. The study was open-label, the cited results were a company headline release rather than the complete peer-reviewed report, and “did not establish noninferiority” is not the same statement as proving inferiority for every outcome or every patient. Full methods and results matter. [3]

Approval status and what is still being studied

Novo Nordisk submitted CagriSema for U.S. weight-management approval in December 2025 based on REDEFINE 1 and REDEFINE 2. In February 2026, the company said an FDA decision was anticipated by late 2026. As of this review, the FDA says cagrilintide is not a component of an approved drug and has not been found safe and effective for any condition. [3] [4] [5]

The research program is continuing. REDEFINE 3 is a cardiovascular-outcomes study designed to examine major cardiovascular events and other outcomes over a much longer follow-up than the pivotal weight-loss trials. Its registration shows that an important outcomes question is being tested; it does not provide the answer before results are reported. [6]

How to read CagriSema headlines

1. Check the population. Results in adults without diabetes and adults with type 2 diabetes are not interchangeable. [1] [2]
2. Check the estimand. The −20.4% treatment-policy result and −22.7% adherence-estimating result answer different questions. [1] [4]
3. Separate placebo-controlled evidence from head-to-head evidence. REDEFINE 4 is the direct tirzepatide comparison, and it missed its noninferiority endpoint. [3]
4. Look for complete peer-reviewed results, especially for safety, discontinuation, missing data, and subgroup findings. [1] [2] [3]
5. Treat an FDA submission as a request for review, not an approval, prescription label, launch date, price, or insurance promise. [3] [5]
6. Avoid products sold as research peptides or compounded CagriSema. FDA states that cagrilintide cannot lawfully be used in compounding and is not a component of an approved drug. [5]

What this means for treatment decisions today

CagriSema’s trial results make it a notable candidate, but they do not create a current treatment option. Someone choosing weight-management care now should compare treatments that are actually approved and available, using their medical history, goals, side-effect risks, contraindications, access, and follow-up needs with a licensed clinician. [5] [3]

Do not stop semaglutide, tirzepatide, or another prescription while waiting for CagriSema. Do not use a trial percentage as a personal forecast. If approval occurs, the final FDA label—not a development presentation—will define the authorized indication, dosing, warnings, and evidence reviewed for U.S. use. [5] [3]

The bottom line

CagriSema combines semaglutide with the amylin analogue cagrilintide and produced substantial average weight loss in two phase 3 trials. The strongest interpretation is narrower than the hype: placebo-controlled efficacy is established in the studied populations, gastrointestinal events were frequent, results differed by analysis and diabetes status, and the head-to-head tirzepatide study missed its noninferiority goal. [1] [2] [3]

The medicine remains investigational while FDA review and longer-term studies continue. Until an approval and label exist, CagriSema should be understood as a promising but unfinished evidence story—not a product to buy, compound, or use in place of currently prescribed care. [6] [3] [5]